{
    "clinical_study": {
        "@rank": "158019", 
        "arm_group": {
            "arm_group_label": "A single-arm study", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Accumulating evidence suggests a role of G protein-coupled inwardly-rectifying potassium\n      (GIRK) channel in the pathology of excitement of nerve, and the medicine with the action\n      (like the Tipepidine Hibenzate) is expected as a new  curative medicine of Attention Deficit\n      / Hyperactivity Disorder (AD/HD).\n\n      The purpose of this research is to confirm the effect by carrying out the additional dosage\n      of the Tipepidine  Hibenzate  to the AD/HD patients.\n\n      If suggestion is obtained by this research about the effect on AD/HD of Tipepidine\n      Hibenzate, it can contribute to development of the medical treatment  of AD/HD."
        }, 
        "brief_title": "An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Attention Deficit Disorder With Hyperactivity", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "[Inclusion Criteria]\n\n          1. Attention-Deficit/Hyperactivity Disorder (AD/HD) for DSM-IV TR criteria.\n\n          2. Patients are treated with Atomoxetine, Methylphenidate, atypical antipsychotic drugs\n             (risperidone, olanzapine, quetiapine, perospirone, aripiprazole, blonanserin,\n             paliperidone) or not treated.\n\n          3. Patients are stable for 4-weeks for medication.\n\n        [Exclusion Criteria]\n\n          1. Patients with a previous hypersensitivity to Tipepidine Hibenzate.\n\n          2. Patients treated with typical antipsychotics and selective norepinephrine reuptake\n             inhibitor (NRI) except atomoxetine and stimulants except methylphenidate.\n\n          3. Pregnant or breast-feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835093", 
            "org_study_id": "G24061"
        }, 
        "intervention": {
            "arm_group_label": "A single-arm study", 
            "intervention_name": "Tipepidine Hibenzate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chiba", 
                    "country": "Japan", 
                    "state": "Chuo-ku", 
                    "zip": "260-8670"
                }, 
                "name": "Department of Psychiatry, Chiba University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Tipepidine for ADHD", 
        "overall_official": {
            "affiliation": "Chairman, Department of Psychiatry, Chiba University Graduate School of Medicine", 
            "last_name": "Masaomi Iyo, MD,PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The ADHD Rating Scale-IV obtains parent ratings regarding the frequency of each ADHD symptom based on DSM-IV criteria.\nThe ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items).", 
            "measure": "ADHD Rating Scale-IV (ADHD-RS) Japanese Version", 
            "safety_issue": "Yes", 
            "time_frame": "Changes from baseline in ADHD-RS at 4-weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835093"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chiba University", 
            "investigator_full_name": "Tsuyoshi Sasaki", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "24493927", 
            "citation": "Sasaki T, Hashimoto K, Tachibana M, Kurata T, Okawada K, Ishikawa M, Kimura H, Komatsu H, Ishikawa M, Hasegawa T, Shiina A, Hashimoto T, Kanahara N, Shiraishi T, Iyo M. Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014 Jan 24;10:147-51. doi: 10.2147/NDT.S58480. eCollection 2014."
        }, 
        "secondary_outcome": {
            "description": "The DN-CAS is an assessment battery designed to evaluate cognitive processing. It was developed to integrate theoretical and applied areas of psychological knowledge using cognitive processing theory and tests designed to measure\u2014Planning, Attention, Simultaneous, and Successive Processing (PASS)\u2014in individuals ages 5-17.\nThis assessment facilitates mental health professionals in the identification of Attention-Deficit/Hyperactivity Disorder, Traumatic Brain Injury, learning disabilities, Mental Retardation, and giftedness.", 
            "measure": "Cognition using DN-CAS (Das-Naglieri Cognitive Assessment System) Japanese Version", 
            "safety_issue": "Yes", 
            "time_frame": "Change from baseline in the scores of battery at 4-weeks"
        }, 
        "source": "Chiba University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiba University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}